Alzinova AB (publ) (STO:ALZ)

Market Cap	179.67M
Revenue (ttm)	16.81M
Net Income (ttm)	-20.55M
Shares Out	89.17M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	33.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	162,328
Average Volume	296,952
Open	1.994
Previous Close	1.986
Day's Range	1.990 - 2.040
52-Week Range	0.949 - 4.620
Beta	1.24
RSI	44.59
Earnings Date	Apr 24, 2025

About Alzinova AB

Alzinova AB (publ), a biopharmaceutical company, develops immunotherapies treatment for Alzheimer’s disease in Sweden. Its lead product candidate is ALZ-101, an active therapeutic oligomer-specific vaccine for the treatment of Alzheimer’s disease, which has completed part A of phase 1b study; and ALZ-201, a monoclonal antibody that neutralizes the toxic oligomers. The company is developing a humanized version of ALZ-201 in patients with Alzheimer’s disease that is in phase 1 clinical study. The company was incorporated in 2011 and is based in M...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ALZ

Financial Performance

In 2024, Alzinova AB's revenue was 16.81 million, a decrease of -15.41% compared to the previous year's 19.87 million. Losses were -20.55 million, 24.7% more than in 2023.